Hospitals Struggle To Supply COVID-19 Teams With The Medicines They Need
Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.
You may also be interested in...
Industry wonders how emergency agency's COVID-19 public-private partnerships will fit in with the others.
The USP is developing a risk model to assess whether pharmaceutical supply chains are strong or weak based on demand for reference standards.
US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.